Exparel Injection Effect on Postoperative Opioid Usage
- Conditions
- Parathyroid AdenomaThyroid
- Interventions
- Registration Number
- NCT04085913
- Lead Sponsor
- University of Missouri-Columbia
- Brief Summary
The question proposed by this study, is one of patient outcomes. Does intraoperative injection of Exparel decrease postoperative use of opioid pain medications in patients undergoing thyroid and parathyroid surgery? The trial seeks to assess the effect that Exparel has on postoperative pain control.
- Detailed Description
Patients will be identified in clinic as good candidates for surgical intervention based on current standard of care. Once participants are consented, they will be randomly placed into one of three categories. The first category being patients undergoing surgery with local injection of lidocaine and epinephrine as is current practice. The second category of patients will undergo surgery with local injection of bupivacaine HCL and epinephrine preincision. The third group will undergo surgery with local injection of lidocaine and epinephrine preincision and Exparel postincision. As stated above, all patients will undergo surgery as planned, which will be standard of care, with the exception of the local anesthetic and timing of the injection. Postoperatively, patient's pain scores and opioid usage will be evaluated. Patients will be monitored by either using the patient's electronic medical record or by a pain journal that will be provided to the patients. The patients will record their pain using a scale of 1-10 with the FACES scale, as well as medication usage. Patients will return to their first postoperative appointment to further discuss their pain levels as well as medication usage. An ANOVA test will be used to determine if there is a significant difference in the amount of opioids taken postoperatively, in oral morphine equivalents, between these three groups. Opioid usage will then be compared between participants in different categories of local anesthetic to determine if there is an effect of postoperative opioid usage between different anesthetics.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 100
- Patients over the age of 18 years Patients requiring parathyroid/thyroid surgery based on the standard of care English as primary language
- Patients under the age of 18 years Patients with previous history of opioid abuse Patients with a true allergy to any local anesthetic Patients with a true allergy to any opioid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Current Practice Lidocaine Epinephrine Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice. Exparel Injection Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision Bupivicaine HCL Bupivacaine Hydrochloride-EPINEPHrine Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
- Primary Outcome Measures
Name Time Method Incidence of opioid use when given Exparel intraoperatively After surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment. Utilizing pain scale daily diary, we will evaluate the incidence of opioid usage in patients that have undergone thyroid/parathyroid surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Missouri
🇺🇸Columbia, Missouri, United States